Janux Therapeutics (NASDAQ:JANX) Share Price Breaks Above 50 Day Moving Average – Time to Sell?

Janux Therapeutics, Inc. (NASDAQ:JANX)’s stock price crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $17.49 and traded as high as $17.81. Janux Therapeutics shares last traded at $17.63, with a volume of 852,234 shares.

Key Stories Impacting Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $40 from $36 and reiterated its outperform rating, implying substantial upside from the cited $17.63 share price. Wedbush raises Janux price target
• Positive Sentiment: Truist raised its target to $27 from $26 and maintained a buy rating, signaling continued confidence in JANX. Truist analyst recommendations
• Positive Sentiment: Janux reported a third-quarter loss of $0.34 per share, narrower than analysts’ expected loss of $0.45–$0.47. Revenue of $9.29 million also exceeded the $8.03 million estimate. The results beat expectations, although the company remained loss-making. Janux third-quarter 2026 results
• Neutral Sentiment: Janux said it dosed the first patient in the Phase 1 study of JANX013 in combination with JANX007, marking progress in its clinical pipeline; the update does not establish how the treatment will perform. Janux business highlights
• Negative Sentiment: Barclays raised its target only to $15 from $14 but kept an underweight rating, placing its target below the cited share price and underscoring a bearish view that contrasts with other analysts. Barclays analyst recommendations

Wall Street Analyst Weigh In

A number of research firms recently weighed in on JANX. Guggenheim decreased their price target on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a research report on Friday, August 7th. TD Cowen upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Friday, October 16th. HC Wainwright reaffirmed a “buy” rating on shares of Janux Therapeutics in a research report on Monday, October 19th. Finally, Barclays increased their target price on shares of Janux Therapeutics from $14.00 to $15.00 and gave the stock an “underweight” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $36.92.

Janux Therapeutics Price Performance

The business has a 50 day moving average price of $17.49 and a two-hundred day moving average price of $15.42. The stock has a market cap of $1.08 billion, a PE ratio of -11.09 and a beta of 2.44.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, November 5th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.13. The company had revenue of $9.29 million for the quarter, compared to analyst estimates of $8.03 million. On average, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.70 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Janux Therapeutics during the 2nd quarter valued at $94,228,000. Bank of America Corp DE acquired a new position in Janux Therapeutics in the second quarter valued at $13,985,000. Nantahala Capital Management LLC acquired a new position in Janux Therapeutics in the second quarter valued at approximately $12,440,279. Irenic Capital Management LP purchased a new position in Janux Therapeutics during the first quarter valued at approximately $10,645,000. Finally, Algert Global LLC lifted its position in shares of Janux Therapeutics by 150.5% during the 2nd quarter. Algert Global LLC now owns 1,110,889 shares of the company’s stock worth $17,063,000 after buying an additional 667,492 shares during the period. 75.39% of the stock is owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.